Ignite Creation Date:
2024-05-06 @ 1:20 PM
Last Modification Date:
2024-10-26 @ 1:12 PM
Study NCT ID:
NCT03998553
Status:
COMPLETED
Last Update Posted:
2020-01-28
First Post:
2019-06-03
Brief Title:
Study for Obtaining Mature Oocytes by in Vitro Maturation in Oocyte-donor Women
Sponsor:
Instituto Valenciano de Infertilidad IVI VALENCIA
Organization:
Instituto Valenciano de Infertilidad IVI VALENCIA
Study Overview
Official Title:
Study for Obtaining Mature Oocytes by in Vitro Maturation in Oocyte-donor Women
Status:
COMPLETED
Status Verified Date:
2020-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IVM
Brief Summary:
In vitro maturation IVM is a technique for obtaining potentially fertilizable oocytes from immature oocytes An oocyte must be mature both nuclearly and cytoplasmically in order to be competent in the reproductive process Nuclear maturation involves an oocyte in metaphase II stage and is easily evaluated for its morphology However cytoplasmic maturation can only be evaluated by in vitro fertilization of that oocyte A mature nuclear and cytoplasmic oocyte is one capable of producing a viable embryo This study aims to fine-tune the in vitro maturation IVM technique to achieve nuclear mature oocytes ie to mature the oocytes up to the metaphase II stage In addition an artificial oocyte activation AOA will be carried out to check the cytoplasmic maturation of the oocytes avoiding the generation of potentially viable embryos
The aim of this study is to evaluate the response to the strategy stimulation with highly purified human menopausal gonadotropin hMG-HP administered for three days in association with a standard methodology of in vitro oocyte maturation IVM to be performed on oocyte donors
The correct functioning of this IVM technique would mean a reduction in the costs of ovarian stimulation treatments as lower doses and shorter stimulation times are required which implies lower risks for women derived from the medication and less stress for them
The aim of this study is to evaluate the response to the strategy stimulation with highly purified human menopausal gonadotropin hMG-HP administered for three days in association with a standard methodology of in vitro oocyte maturation IVM to be performed on oocyte donors
The correct functioning of this IVM technique would mean a reduction in the costs of ovarian stimulation treatments as lower doses and shorter stimulation times are required which implies lower risks for women derived from the medication and less stress for them
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None